This disruption of the interaction between the CLL microenvironment and the surrounding stroma through SYK inhibitors attenuates the integrin-/chemokine-mediated protective stromal survival effects in CLL (72). Here, SYK is linked to B-cell chronic lymphocytic leukemia.